Amgen (AMGN) and AstraZeneca (AZN) report that their phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75), and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment.
Shares of both companies are flat in after-hours trade.
Latest posts by Anne-Marie Jackson (see all)
- SF Hospital Slaps New Parents with $19K Bill for Baby Treatment - Mar 19, 2019
- Furious Trump Blasts Harley-Davidson for Moving Production Overseas - Mar 19, 2019
- Warning! MRI Machines Could Poison You - Mar 19, 2019